Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid and small caps outperform
Mon, 3 Aug 01:30 pm

After trading on a flat note during the morning session of the day, the Indian equity markets have stayed above the dotted line in the post noon trading session. Gains are led by stocks from banking and auto stocks. IT stocks are however trading in the red.

The BSE-Sensex is trading up 70 points (0.3%) and the NSE-Nifty is trading up by 13 points (0.2%). The S&P BSE Midcap index and the S&P BSE Smallcap index are trading up by 0.5% and 0.9% respectively. Gold prices, per 10 grams, are trading at Rs 24,800 levels. Silver price, per kilogram, is trading at Rs 33,850 levels. Crude oil is trading at Rs 2,985 per barrel. At the time of writing, the rupee stood at 63.99 to the US dollar.

Stocks in the automobile sector are trading on a mixed note with Force Motors leading the gains and TVS Motors bearing the losses. According to financial times, Bajaj Auto has reported a 3% increase in its total sales for the month of July, 2015. This was registered at 3,30,231 units as against 3,19,292 units in the same month of 2014. Motorcycle sales during the month rose 5% YoY while the sales of commercial vehicles witnessed a decline of 7% YoY. Exports for the concerned month came in at 1,64,690 units, a YoY decline of 3%. Presently the scrip of Bajaj Auto is trading down by 0.7%.

Pharma stocks are trading mixed with Novartis and Pfizer witnessing maximum buying interest. As per a leading financial daily, GlaxoSmithKline pharmaceuticals (GSK pharma) has announced its Greenfield manufacturing facility at Bengaluru will be operational by 2017. The facility with an installed capacity of over 9 bn tablets and capsules per year will supply a range of solid dose form products. It will come with an investment of up to Rs 10 bn. As stated by the company, the new unit is part of the strategic plan to rationalize, streamline and reduce costs in the supply network, whilst increasing capacity to meet the growing demands for important medicines. On a separate note, the company has also halved the prices for its Seretide inhaler in India to match that of Cipla's brand Sereflo. Stock of GSK pharma is currently trading up 0.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid and small caps outperform". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.